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ABSTRACT 
Psoriasis is an autoimmune disorder of the skin characterized by relapsing episodes of inflammatory lesions 
and hyperkeratotic plaques with worldwide occurrence of around 2–5%. Psoriasis is a disease known to be caused by multitude of 
both genetic and environmental factors such as trauma, drugs, infection, alcohol, smoking and stress but its accurate origin is still not 
known. Further, available treatment options are associated with both inappropriate cosmetic appearance and related toxicities leading 
to poor patient compliance in long term use. Nanotechnology based drug delivery system has immense potential to enhance the 
bioavailability and effectiveness of drugs in their dosage forms, especially lipophilic drugs. Lipid based carrier system can overcome 
the lipid imbalance and normal moisturizing factors. Nanoemulsions, as one of a new carrier apparently have the prospective to 
conquer numerous problems related with topical antipsoriatic therapy. This delivery system could perhaps offer a good alternative in 
topical psoriasis treatment. Not only on how nanoemulsions prepared, but it depends on the active ingredients used and the selection 
of oil could as well enhance the efficiency of topical treatment towards psoriasis. A good combination of both active and suitable 
oils would result a better treatment and better effect. 
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1. INTRODUCTION OF PSORIASIS 
Psoriasis is an autoimmune disorder of the skin 
characterized by relapsing episodes of inflammatory 
lesions and hyperkeratotic plaques with worldwide 
occurrence of around 2–5% The psoriasis can be 
classified on the basis of extent of 
inflammatory process, localization of rash, severity of 
the patient condition, and other clinical traits into 
chronic plaque, guttate, pustular, erythroderma, Scalp, 
nail, facial, flexural psoriasis and Psoriatic arthritis as 
shown in table 1. Amongst these, chronic plaque 
psoriasis (CPP) represents major occurrence proportion 
with equivalent likelihood in both sexes and early onset 
before the age of 40 years. 
1 
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Table 1: Classification of Psoriasis 
Plaque 
psoriasis 
Most people have plaque psoriasis. This looks like patches of pink or 
red skin covered with silvery white scales (sometimes called plaques). 
The silvery white scales are dead skin cells. The patches are slightly 
raised from the surface of the skin. 
 
Guttate 
psoriasis 
This looks like lots of small red scaly patches dotted across your skin. 
These patches can cover quite a large area of your skin. 
 
Pustular 
psoriasis 
This can be a severe type of psoriasis where lots of small blisters 
appear on your skin. It needs emergency medical attention. 
 
Erythrodermic 
psoriasis 
This is a rare and severe type of psoriasis. Most or all of the skin on 
your body becomes red and inflamed. It needs emergency medical 
attention. 
 
Scalp, nail, 
facial and 
flexural 
psoriasis 
Psoriasis can be more difficult to treat on some parts of the body. 
Flexural psoriasis happens in skin folds, armpits, under the breast, 
between buttocks and in the groin area where it can affect the genitals. 
 
 
 
2. PATHOGENESIS OF PSORIASIS 
Psoriasis is a disease known to be caused by multitude 
of both genetic and environmental factors such as 
trauma, drugs, infection, alcohol, smoking and stress but 
its accurate origin is still not known. It negatively 
produces both physical and psychological impacts on 
patients' health and quality of life involving social 
disgrace, state of agony, distress, and physical disability. 
This strained situation drives the patients to contemplate 
suicide amounting to around 30% cases. Unlike normal 
skin, pathological progression of psoriasis is supposed to 
rely on multitude of coherent events involving the 
activation of circulating immune cells and their 
secreted signaling molecules like cytokines, chemokines 
and growth factors. These all events further progress to 
mark hyperkeratosis, congealing of epidermis and 
neovascularization of circulating immune cells and their 
secreted signaling molecules as shown in figure 1. 
Cytokines play an important role in progression of 
psoriasis. Major cytokines include tumor necrosis factor 
alpha (TNF-α), Interleukin-23 (IL-23) and IL-17 which 
aids in the production of other proinflammatory 
cytokines and psoriasis lesions formation 
1
. Several of 
these pro-inflammatory cytokines e.g. TNFα, IL-12 and 
IL-23 rely on nuclear factor kappa B (NF-κB) as a 
downstream mediator of their effects on a 
transcriptional level. Accordingly, increased levels of 
activated NF-κB are found in psoriasis skin 
compared with healthy skin. 
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Figure 1: Different Events in the Pathogenesis of Psoriasis 
 
3. AVAILABLE TREATMENT STRATEGIES 
FOR PSORIASIS 
Generally, treatment choices for psoriasis involve three 
main modes namely topical therapy, phototherapy and 
systemic therapy. For psoriasis treatment topical 
therapies are considered first. Phototherapy is suggested 
in case of non-effectiveness of topical therapy or 
relentlessness of the psoriasis condition, which is 
followed by systemic medications as shown in table 2 
2
. 
Among the currently available treatments, none of the 
treatment for psoriasis is found to be safe, effective and 
able to completely cure the disease. Further, available 
treatment options are related with both inappropriate 
cosmetic appearance and related toxicities leading to 
poor patient compliance in long term use. Phototherapy 
and systemic agents exhibit numerous ill effects such as 
hepatotoxicity, renal toxicity, hypertension, 
hyperlipidemia and skin cancer. Moreover the currently 
available treatments based on conventional formulation 
for psoriasis are associated with problems like increased 
dosing frequency, increased side effects and decreased 
safety profile for long term use. Among the currently 
available treatments, none of the treatment for psoriasis 
is found to be safe, effective and able to completely cure 
the disease. Further, available treatment options are 
associated with both inappropriate cosmetic appearance 
and related toxicities leading to poor patient compliance 
in long term use. Therefore improvement of a perfect 
therapy for psoriasis is a great confront. The lack of 
effective and safe treatment for psoriasis has created 
needs to develop and implement novel approach with a 
view to make the therapy more useful and acceptable 
3, 4
. 
To overcome the drawbacks of conventional dosage 
forms, formulation development is aimed to design drug 
cargo exhibiting ease of administration, reduced dosing 
frequency, and sustained release for improved 
therapeutic benefit to psoriatic patients. 
 
Table 2: Available treatment strategies for psoriasis 
Type  of Therapy Class Drugs in Class 
Topical 
Tars Tar 
Antracens  Dithranol 
Psoralens  Trioxysalen – Methoxsalen  
Others 
Fumaric acid – vitamin D (Calcipotriol, Tacalcitol, Calcitriol) –
Tazarotene  
Phototherapy  
 
Artificial or natural light sources 
Systemic  
Psoralen Methoxsalen – Bergapten- Trioxysalen  
Retinoids  Etretinate – Acitretin  
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4. NEED OF TOPICAL NANOTECHNOLOGICAL 
BASED DRUG DELIVERY SYSTEM 
Nanotechnology based drug delivery system has 
immense potential to enhance the bioavailability and 
effectiveness of drugs in their dosage forms, especially 
lipophillic drugs. For the effective treatment of 
cutaneous originated disorders such as Psoriasis, the 
drug should ideally be confined to the surface or within 
the site of application without appreciable systemic drug 
absorption. Thus, the site of application forms the target 
of topical drug delivery systems. Although topical drug 
delivery offers certain advantages over systemic delivery 
for selected drugs and conditions, the resistance against 
drug transport across skin barrier remains a major 
challenge to efficient drug delivery by this route. There 
is also potential of skin irritation or contact dermatitis 
arising from one or more components in the topical 
formulation. In some cases poor permeability of some 
drugs through the skin leads to poor pharmacological 
response. Possibility of allergic reactions and 
degradation of drug by the enzymes present in epidermis 
may create problems. Rigidization of psoriatic skin has 
been attributed to a rise in the levels of cholesterol and 
fall in the levels of ceramides. Apart from this, normal 
moisturizing factors (NMFs) like water are almost 
absent in the psoriatic skin of a patient. As a result of 
these factors, targeting drug molecule in a vehicle to the 
psoriatic tissues using topical route poses a big 
challenge. Lipid based carrier system can overcome the 
lipid imbalance and normal moisturizing factors. The 
most widely used drug delivery systems include lipid 
based nanoparticles i.e. nanoemulsions, solid lipid 
nanoparticles, lipid nanocapsules, nanosuspension, 
liposomes, liquid crystalline nanoparticles, lipid-drug 
conjugates) or polymer based nanocarriers (polymeric 
nanoparticles, polymeric micelles, polymer-drug 
conjugates) as shown in table 3 
3
. 
 
Table 3: List of topical novel drug delivery systems for psoriasis 
Novel Drug Delivery Systems Anti-Psoriatic Drug Ref 
Liposome-gel Hydrocortisone 4 
Transfersome in gel Tacrolimus 5 
Drug β-Cyclodextrine complexes into SLNs Hydrocortisone 6 
Cyclodextrin inclusion complex incorporated in multivesicular liposomes Fluocinolone acetonide 7 
Chitosan coated microemulsion Methoxsalen 8 
PLGA/PLA nanoparticles (plus zinc) Betamethasone 9 
PLGA (poly(D,L-lactic-co-glycolic acid)) nanoparticles Betamethasone 10 
PLGA nanoparticles Ciclosporine 
Dexamethasone 
11 
13 
PLGA microspheres Clobetasol-17- 
propionate 
12 
Poly(ε-caprolactone) (PCL) nanocapsule Dexamethasone 14 
PCL nanoparticles Hydrocortisone 15 
Polymeric micelle (PEG-dihexPLA diblock copolymer) Ciclosporine 16 
Poly(NIPAM-co-BA) nanogel Methotrexate 17 
Methoxy-poly(ethylene glycol)-dihexyl substituted polylactide (MPEG- 
dihexPLA) diblock copolymer micelle 
Tacrolimus 18 
Niosome Anthocyanin complex 
Dithranol 
Methotrexate 
19 
20 
21 
Lecithin/chitosan nanoparticles Betamethasone 
Clobetasol-17- 
propionate 
10 
22 
Liposome Tacalcitol 
Clobetasol-17- 
propionate 
Dithranol 
Tacrolimus 
Tretinoin 
Triamcinolone 
23 
24 
21 
25 
10 
26 
27 
Pegylated liposomes Calcipotriol 28 
Transferosome Dexamethasone 
Hydrocortisone 
Triamcinolone 
29 
30 
 
Flexible vesicles and conventional vesicles Cyclosporine 31 
Deformable liposomes Methotrexate 32, 33 
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Ethosome Ciclosporine 
Methotrexate 
Psoralen 
Tacrolimus 
Tretinoin 
Tretinoin 
34 
35 
36 
37 
26 
SLNs (Solid lipid nanoparticles) Betamethasone 
Ciclosporine 
Clobetasol-17- 
propionate 
Dithranol 
Methoxsalen. 
Mometasone furoate 
Prednicarbate 
Psoralen 
Tretinoin 
Triamcinolone 
38 
39 
40 
41 
42 
43 
26 
44 
45 
46 
47 
SLN-hydrogel Betamethasone 
dipropionate and 
calcipotriol 
Halobetasol 
Tacrolimus 
48 
49 
50 
Nanostructured lipid carriers (NLCs)-hydrogel Acitretin 51 
NLCs Calcipotriol and 
methotrexate 
Clobetasol-17- 
propionate 
Fluocinolone acetonide 
Methotrexate 
Methoxsalen 
Psoralen 
Tacrolimus 
Tretinoin 
52 
53 
54 
55 
62 
47 
56 
26 
Microemulsions in hydrogel Betamethasone 
dipropionate and 
salicylic acid 
57 
Microemulsion Dithranol 
Methoxsalen 
Tacrolimus 
58 
59 
60 
Nanoemulsion Methoxsalen 61 
Microemulsions in hydrogel Methoxsalen 5 
Liquid crystalline nanoparticles Cyclosporine A 
Tacrolimus 
64 
65 
 
5. NANOEMULSIONS AS TOPICAL 
DELIVERY FOR ANTIPSORIATIC DRUGS 
Nanoemulsions are emulsions with droplet size on the 
order of 100 nm. A typical nanoemulsion contains oil, 
water and an emulsifier. Nanoemulsions can be rendered 
into several dosage forms, like liquids, creams, sprays, 
gels, aerosol, and foams; and can be administered by 
equally varying routes like topical, oral, intravenous, 
intranasal, pulmonary and ocular. They possess higher 
solubilization capacity than simple micellar dispersions, 
greater kinetic stability than coarse emulsions and have 
found use in cosmetic industry 
66
. 
 
5.1. Advantages of Nanoemulsion 
Their long-term physical stability is a direct 
consequence of small droplet size, which impairs 
conventional destabilization phenomena like creaming, 
sedimentation and coalescence. When administered 
topically, miniscale size of droplets in nanoemulsion 
and their capability to solubilize very hydrophobic drugs 
provides a pathway to drastically increase rate of drug 
dissolution and subsequently expected systemic 
bioavailability through trancellular route as shown in 
figure 2. Drug release from nanoemulsion involves 
partitioning of it from oil into surfactant layer and then 
into aqueous phase, thus avoids occlusive effects 
67
. 
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Figure 2: Mechanism of absorption of Nanoemulsion 
6. METHODS OF PREPARATION OF 
NANOEMULSION 
There are basically two methods of preparation of 
nanoemulsion as shown in figure 3. High energy 
emulsification methods generate highly disrupting forces 
that break down the oil and water phases, causing them 
to intersperse and form nanometer-sized droplets. 
Whereas low energy emulsification methods include 
heat, stirring and phase inversion 
68
. 
6.1 High Pressure Homogenization 
This is highly efficient method of preparation of 
nanoemulsion in which forcefully introduction of oil and 
water along with surfactants, cosurfactants are passed 
through a small orifice at high pressure. At first, 
emulsion is formed with large volume fraction of 
dispersed phase, which may be diluted later on. Excess 
amount of surfactants are added to avoid coalescence
73, 
80
.  
6.2 Microfluidisation 
In this method water and oil are introduced through 
small orifice by pressure pump from opposite direction 
into mixing area, where they mixed with other high 
shear and converted into small droplets which in turn 
used to prepared nanoemulsion 
58
.  
6.3 Sonication 
It is widely used method in which probe sonicator is 
placed in the mixture oil and water with surfactants, 
cosurfactants to give mechanical force by which 
dispersion is converted into small sized droplets 
61
.  
6.4 Phase inversion temperature technique 
In this technique at room temperature oil, water and 
surfactants are mixed and then temperature is increased, 
then surfactant mixed in the oily phase. Due to change in 
temperature phase inversion prevents coalescence and 
produce stable nanoemulsions 
59
.  
6.5 Solvent displacement method 
In this method nanoemulsions can be prepared by 
pouring the organic phase containing oil dissolved in a 
solvent into aqueous phase having surfactants at room 
temperature. The preparation of nanoemulsion occurs by 
diffusion of organic solvent, evaporated by vacuum. 
Small sized droplets of nanoemulsion can be prepared 
by taking appropriate ratio of solvent to oil. 
73
 
6.6 Spontaneous emulsification 
In the solution of oil and surfactant water is added at 
constant temperature and mixed lightly to produce o/w 
nanoemulsions. The preparation of nanoemulsion 
depends on surfactant structure, its concentration, 
interfacial tension, interfacial and bulk viscosity, phase 
transition region 
68, 74, 75
. 
 
Figure 3: Methods of Preparation Nanoemulsion 
Methods of 
Preparation of 
Nanoemulsion 
High-Energy 
Emulsification 
High pressure 
homogenization 
Ultrasonication 
Microfluidization 
Low-Energy 
Emulsification 
Spontaneous 
emulsification 
Heat 
stirring/vortexing 
Oil phase titration 
Aqueous phase 
titration 
Solvent 
displacement/ 
diffusion 
Phase Inversion 
Temperature /Point 
Rapid cooling of selected 
microemulsion state 
Dilution with water 
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7. COMPONENTS IN THE TOPICAL 
NANOEMULSION FORMULATIONS FOR 
ANTIPSORIATIC DRUGS 
7.1 Oil Phase 
Selection of oil phase such as saturated and unsatuated 
fatty acids/fatty acid esters like castor oil, coconut oil, 
corn oil, cottonseed oil, evening primrose oil, fish oil, 
jojoba oil, lard oil, linseed oil, mineral oil, olive oil, 
peanut oil, PEG-vegetable oil, perflurochemicals, pine 
nut oil, safflower oil, sesame oil, soybean oil, squalene, 
sunflower oil, wheatgerm oil can be done. Oil phase 
helps in penetration of drugs. Mostly antipsoriatic drugs 
are lipophilic and have a log P value of 3, which makes 
it suitable for being encapsulated in emulsion. 
Sometimes combination of oils is used to encapsulate 
antipsoriatic drugs 
73
. 
7.2 Surfactant  
Selection of surfactant is used to decrease the interfacial 
tension and makes a stable emulsions having requisite 
particle size, but which also ensure minimal skin 
irritancy there are basically four types of surfactants i.e. 
nonionic, zwitterionic cationic, anionic.. Commonly 
used surfactants include Tween®, Cremophor®, 
Transcutol® P, Plurol Oleique®, Plurol Isostearique® 
and Labrasol® , Lecithin, Organogels 
75
. 
7.3 Co-surfactant 
Cosurfactants are generally used to modify the curvature 
and fluidity of the interfacial fillm, leading to the 
decrease of interfacial tension. Cosurfactants are short 
and medium chain alcohols and polyglyceryl derivatives, 
including ethanol, isopropanol, isopropyl myristate and 
propylene glycol (PG) 
73
.  
7.4 Other Excipients 
Antioxidants (a-tocopherol, ascorbic acid) Tonicity 
modifiers (glycerol, sorbitol, xylitol) pH adjustment 
agents (NaOH or HCl) Preservatives, aqueous phase 
(sodium chloride and buffer salts) and penetration 
enhancers, Viscosity enhancing agents (e.g., Carbopol®, 
Aerosil®, gelatin) are incorporated to reduce the fluidity 
and generate the desired final consistency of the product 
69
. 
8. CHARACTERIZATION OF 
NANOEMULSION  
8.1. Drug-excipients compatibility studies: Excipients 
are determined by Fourier Transform Infrared 
Spectroscopy (FTIR) and UV Spectrophotometry studies 
can be used for the determination of physicochemical 
compatibility and interactions between the drug and 
excipients. Drug-excipient interactions recommended 
that 1:1 ratio of drug and excipient maximizes the 
possibility of interaction and helps in easier detection of 
incompatibilities 
61
. 
8.2. Globule size distribution & polydispersity index: 
The mean globule size of the nanoemulsion can be 
determined by Photon Correlation Spectroscopy (PCS) 
using a Zeta sizer. This analytical results reveals the 
mean diameter of the particle at 25 °C, and at an angle 
of 90 degree (n=10). The PCS analysis yields a mean 
diameter (z-average) as a light intensity-weighed size of 
bulk population and the polydispersity index as a 
measurement for the width of a globule size distribution 
60
. 
8.3. Zeta potential: The electrophoretic mobility can be 
obtained by a Laser Doppler Anemometer connected 
with the zeta sizer instrument.  Dilute suitable amount of 
sample (50-100μL) with 5mL of water (0.45μm) and 
inject in the electrophoretic cell of the instrument where 
a potential set at ±150mV. The zeta potential values can 
be calculated by the instrument software using 
Smoluchosky equation 
61
. 
8.4. Morphology by transmission electron 
microscopic (TEM): TEM helps to visualize the 
inherent matrix of individual globule and its shape. A 
drop of the suitably diluted sample was placed on to a 
holey carbon coated copper grid and left for 10 minutes. 
Then kept grid inverted and apply a drop of 
phosphotungstic acid (PTA) to the grid for 10s. Remove 
excess of PTA by absorbing on a filter paper and 
analyze the grid at particular magnification 
5
. 
8.5. pH: The pH of the formulation can be measured in a 
pH meter 
58
. 
8.6. Viscosity: The viscosity of the nanoemulgel can be 
determined by a Brookfield viscometer which rotates for 
10min at 100 maximum rotations per minute with 
spindle 
57
. 
8.7. Drug content: The amount of drug present in the 
nanoemulgel can be determined by dissolving 5g of 
nanoemulgel in 25ml of phosphate buffer solution at pH 
7.4 by sonication. After sonication filter the solution, 
then filtrate dilute suitably and the take absorbance at 
273nm in UV-Visible spectrophotometer finally 
calculate the percentage of drug content 
56
. 
8.8. Spreadability: Spreadability test can be performed 
by measuring the spreading diameter of the nanoemulgel 
between two glass slides. Weigh about 0.5g of sample 
and place at the centre (within a circle) of the glass plate, 
over which place a second glass plate and press between 
the two slides and measure the spreadability of the gel in 
cm after 5 minutes 
60
. 
8.9. Pseudo Ternary Phase Diagrams: It is 
characterized by a range of physical properties that are 
important determinants of their structure, drug release 
and stability. Pseudo ternary phase diagrams are often 
constructed to indicate the boundaries of the different 
phases as a function of the composition of the aqueous, 
oil and surfactant/cosurfactant components. Mixtures of 
the oil, surfactant and cosurfactant at certain weight 
ratios at ambient temperature (25 ºC) are dilute with the 
aqueous solution under moderate agitation. After 
equilibrium, the combinations of the three components 
that give rise to clear emulsions, shown by visual 
inspection or polarised light microscopy, are mapped on 
the phase diagram as shown in figure 4 
60
. 
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Figure 4: Phase diagram for formulation of 
nanoemulsion 
8.10. In-Vitro release In-vitro release studies can be 
carried out by using dialysis membrane bag method. The 
dialysis membrane is conditioned by soaking in 
phosphate buffer 7.4 for 8 hours. Take drug loaded 
nanoemulgel of about 3mL in the dialysis membrane and 
immerse in 200mL of phosphate buffer solution (pH 
7.4). Withdraw sample of 5mL from the dissolution 
setup at regular intervals for 8 hours and replace an 
equal volume of phosphate buffer (pH 7.4) to maintain a 
sink condition. Analyze samples by using UV 
spectrophotometer at 290nm and calculate the amount of 
drug release and compare with the marketed 
conventional dosage form 
70-71
. 
9. STABILITY OF NANOEMULSIONS 
Emulsion stability is dependent on role of surfactants, its 
composition and the drop size distribution. Major 
instability is due to coalescence in which there is fusion 
of droplets by breaking the film between the two 
globules which in turn increase the size of nanoemulsion 
as shown in figure 5. It can be preventing by adding a 
sufficient amount of surfactant while preparing 
nanoemulsions. Another one is Ostwald ripening in 
which emulsions get destabilized with the passage of 
time due to molecular diffusion and change in droplet 
size of nanoemulsion. There is mass transfer occurs form 
dispersed phase to continuous phase 
72
.   
 
 
 
Figure 5: Physicochemical mechanisms cause 
instability
 
 
10. VARIOUS ANTIPSORIATIC DRUGS LOADED IN NANOEMULSION 
Already extensive research has been done on nanoemulsion loaded antipsoriatic drugs as shown and discussed in table 
4. 
Table 4: Various antipsoriatic drugs loaded in nanoemulsion 
Antipsoriatic Drug Method of Preparation Ingredients used in Nanoemulsion Ref 
Aceclofenac and capsaicin Solvent evaporation method and 
high-pressure homogenization 
method. 
Polyvinyl alcohol ,dichloromethane, 
tween 80, sodium tripolyphosphate, 
polyethylene glycol  
73 
Turmeric oil Emulsification method Tween 20, tween 80, lecithin, labrasol,   
isopropyl   alcohol 
74 
Clobitasol propionate and 
calcipotriol 
Emulsification method Capmul MCM C8 EP, Cremophor RH 
40 and Labrafil 1944 CS 
75 
Betamethasone dipropionate Spontaneous 
Emulsification method 
Babchi oil, eucalyptus 
Oil,  tween 20 and ethanol 
76 
Betamethasone dipropionate 
and salicylic acid 
Aqueous phase titration method Oleic acid, sefsol, tween 20, isopropyl 
alcohol 
77 
Clobetasol propionate  Aqueous phase titration method Eucalyptus oil, tween 20, ethanol, and 
distilled water 
78 
Betamethasone valerate Aqueous phase titration method Sefsol, tween 20, transcutol p 
79 
Cyclosporine High-shear homogenizer Nutmeg oil,  virgin coconut oil, tween 
80,xanthan gum 
80 
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11. CONCLUSION 
Though development has been made in understanding 
the mechanism of action of psoriasis and in make out 
efficient treatments, the exploration for the best 
treatment approach for psoriasis still remains a major 
confront. Many topical cures are available for the 
treatment of psoriasis, but there is a lack of consistency 
of approach which is acceptable for moderate to severe 
psoriasis. Psoriasis is a lasting disease in which the 
patients have to take long term medication treatment. In 
addition, there is still no available delivery system for 
psoriasis which is safe, effective, patient's compliance 
and affordable to completely cure the disease. Lipid 
based carrier system can overcome the lipid imbalance 
and normal moisturizing factors. Nanoemulsions, as one 
of a new carrier apparently have the prospective to 
conquer numerous problems related with topical 
antipsoriatic therapy. This delivery system could 
perhaps offer a good alternative in topical psoriasis 
treatment. Not only on how nanoemulsions prepared, 
but it depends on the active ingredients used and the 
selection of oil could as well enhance the efficiency of 
topical treatment towards psoriasis. A good combination 
of both active and suitable oils would result a better 
treatment and better effect. Nanoemulsion are the best 
suited nano delivery systems to encapsulate and deliver 
poorly water soluble drugs successfully due to their 
inherited properties. Nanoemulsions offer enhanced 
solubilization capacity for poorly soluble drugs, 
increased drug loading, and in turn lead to a higher 
bioavailability of the formulated therapeutic moiety. 
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